Q-omics provides the consensus-scored SFTPB profile across patient tissues and cancer cell-line models. SFTPB expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SFTPB is differentially expressed in 7, with the highest sampling consensus in KIRC. Additionally, SFTPB RNA expression shows 11,357 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, and LSCC as cancer lineages where SFTPB shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SFTPB — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SFTPB survival associations across molecular data types. SFTPB RNA expression shows survival associations in the most cancer types (22), followed by mutation status (5) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SFTPB RNA expression–survival associations across cancer types. High SFTPB expression shows unfavorable associations in KIRC, LUSC, KIRP, LGG and OV, but favorable associations in LUAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SFTPB RNA expression.
This table summarizes SFTPB tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for SFTPB. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SFTPB shows lower tumor expression in KIRC, LUAD and LUSC and higher tumor expression in THCA, KICH and HNSC. The KIRC box plot shows higher SFTPB RNA expression in normal versus tumor tissue (log2 FC = −0.736, t-test p < 0.001).
This table shows molecular features associated with SFTPB in patient tissues and cancer cell lines. In patient samples, SFTPB shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, SFTPB RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
